Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX2843 in Relapsed/Refractory Acute Myeloid Leukemia
NCT04946890Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MRX-2843 in acute myeloid leukemia (AML) (3 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Safety at 28 days and Recommended Phase 2 Dose at 28 days. Status: unknown.
02
Drugs
MRX-2843
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04946890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946890.